1. Park JJ, Lee CJ, Park SJ, et al. Heart failure statistics in Korea, 2020: a report from the Korean Society of Heart Failure. Int J Heart Fail 2021;3:224–236.

2. Seferović PM, Vardas P, Jankowska EA, et al.; National Heart Failure Societies of the ESC member countries (see Appendix. The Heart Failure Association Atlas: heart failure epidemiology and management statistics 2019. Eur J Heart Fail 2021;23:906–914.

3. Lee CJ, Lee H, Yoon M, et al. Heart failure statistics 2024 update: a report from the Korean Society of Heart Failure. Int J Heart Fail 2024;6:56–69.

4. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2017;14:591–602.

5. Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med 2017;376:897.

6. Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol 2020;17:559–573.

7. Park SM, Lee SY, Jung MH, et al.; Committee of Clinical Practice Guidelines, Korean Society of Heart Failure. Korean Society of Heart Failure guidelines for the management of heart failure: management of the underlying etiologies and comorbidities of heart failure. Int J Heart Fail 2023;5:127–145.

8. Solomon SD, McMurray JJV, Claggett B, et al.; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089–1098.

9. Anker SD, Butler J, Filippatos G, et al.; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–1461.

10. Solomon SD, McMurray JJV, Vaduganathan M, et al.; FINEARTS-HF Committees and Investigators. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2024;391:1475–1485.

11. Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC Expert Consensus Decision Pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2023;81:1835–1878.

12. Heidenreich PA, Bozkurt B, Aguilar D, et al.; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2022;145:e895–e1032.

13. McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–3726.

14. Jeong SM, Jung JH, Yang YS, et al.; Taskforce Team of the Obesity Fact Sheet of the Korean Society for the Study of Obesity. 2023 Obesity Fact Sheet: prevalence of obesity and abdominal obesity in adults, adolescents, and children in Korea from 2012 to 2021. J Obes Metab Syndr 2024;33:27–35.

15. Rhee EJ, Kwon H, Park SE, et al. Associations among obesity degree, glycemic status, and risk of heart failure in 9,720,220 Korean adults. Diabetes Metab J 2020;44:592–601.

16. Hwang IC, Choi HM, Yoon YE, et al. Body mass index, muscle mass, and all-cause mortality in patients with acute heart failure: the obesity paradox revisited. Int J Heart Fail 2022;4:95–109.

17. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011;4:324–331.

18. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305–313.

19. Van Gaal LF, Maggioni AP. Overweight, obesity, and outcomes: fat mass and beyond. Lancet 2014;383:935–936.

20. Carbone S, Lavie CJ, Arena R. Obesity and heart failure: focus on the obesity paradox. Mayo Clin Proc 2017;92:266–279.

21. Rothman KJ. BMI-related errors in the measurement of obesity. Int J Obes (Lond) 2008;32:Suppl 3. S56–S59.

22. Ebong IA, Goff DC Jr, Rodriguez CJ, Chen H, Bertoni AG. Mechanisms of heart failure in obesity. Obes Res Clin Pract 2014;8:e540–e548.

23. Carbone S, Lavie CJ, Elagizi A, Arena R, Ventura HO. The impact of obesity in heart failure. Heart Fail Clin 2020;16:71–80.

24. Alpert MA, Lavie CJ, Agrawal H, Aggarwal KB, Kumar SA. Obesity and heart failure: epidemiology, pathophysiology, clinical manifestations, and management. Transl Res 2014;164:345–356.

25. Lembo M, Strisciuglio T, Fonderico C, et al. Obesity: the perfect storm for heart failure. ESC Heart Fail 2024;11:1841–1860.

26. Jung MH, Shin MS. Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges. Korean J Intern Med 2023;38:157–166.

27. Michos ED, Lopez-Jimenez F, Gulati M. Role of glucagon-like peptide-1 receptor agonists in achieving weight loss and improving cardiovascular outcomes in people with overweight and obesity. J Am Heart Assoc 2023;12:e029282.

28. Popoviciu MS, Păduraru L, Yahya G, Metwally K, Cavalu S. Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials. Int J Mol Sci 2023;24:10449.

29. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023;118:3434–3450.

30. Frank RC, Min J, Abdelghany M, et al. Obesity is associated with pulmonary hypertension and modifies outcomes. J Am Heart Assoc 2020;9:e014195.

31. Shu H, Cheng J, Li N, et al. Obesity and atrial fibrillation: a narrative review from arrhythmogenic mechanisms to clinical significance. Cardiovasc Diabetol 2023;22:192.

32. Rafaqat S. Adipokines and their role in heart failure: a literature review. J Innov Card Rhythm Manag 2023;14:5657–5669.

33. Nakamura K, Fuster JJ, Walsh K. Adipokines: a link between obesity and cardiovascular disease. J Cardiol 2014;63:250–259.

34. Feijóo-Bandín S, Aragón-Herrera A, Moraña-Fernández S, et al. Adipokines and inflammation: focus on cardiovascular diseases. Int J Mol Sci 2020;21:7711.

35. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013;93:359–404.

36. Sáinz N, Barrenetxe J, Moreno-Aliaga MJ, Martínez JA. Leptin resistance and diet-induced obesity: central and peripheral actions of leptin. Metabolism 2015;64:35–46.

37. Lieb W, Sullivan LM, Harris TB, et al. Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals. Diabetes Care 2009;32:612–616.

38. Huby AC, Antonova G, Groenendyk J, et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation 2015;132:2134–2145.

39. Huby AC, Otvos L Jr, Belin de Chantemèle EJ. Leptin Induces hypertension and endothelial dysfunction via aldosterone-dependent mechanisms in obese female mice. Hypertension 2016;67:1020–1028.

40. Kim M, Oh JK, Sakata S, et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 2008;45:270–280.

41. Frankel DS, Vasan RS, D’Agostino RB Sr, et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 2009;53:754–762.

42. Bobbert P, Jenke A, Bobbert T, et al. High leptin and resistin expression in chronic heart failure: adverse outcome in patients with dilated and inflammatory cardiomyopathy. Eur J Heart Fail 2012;14:1265–1275.

43. Trayhurn P, Wood IS. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans 2005;33(Pt 5):1078–1081.

44. Bahrami H, Bluemke DA, Kronmal R, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008;51:1775–1783.

45. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263–271.

46. Ter Maaten JM, Damman K, Verhaar MC, et al. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur J Heart Fail 2016;18:588–598.

47. Shen Q, Hiebert JB, Rahman FK, Krueger KJ, Gupta B, Pierce JD. Understanding obesity-related high output heart failure and its implications. Int J Heart Fail 2021;3:160–171.

48. Packer M. Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation 2018;137:1614–1631.

49. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106:473–481.

50. Lopaschuk GD, Folmes CD, Stanley WC. Cardiac energy metabolism in obesity. Circ Res 2007;101:335–347.

51. Sletten AC, Peterson LR, Schaffer JE. Manifestations and mechanisms of myocardial lipotoxicity in obesity. J Intern Med 2018;284:478–491.

52. Oduah MT, Sundaram V, Reddy YN. Epicardial fat in heart failure with preserved ejection fraction: bad actor or just lying around? Card Fail Rev 2023;9:e06.

53. Koepp KE, Obokata M, Reddy YNV, Olson TP, Borlaug BA. Hemodynamic and functional impact of epicardial adipose tissue in heart failure with preserved ejection fraction. JACC Heart Fail 2020;8:657–666.

54. Gorter TM, van Woerden G, Rienstra M, et al. Epicardial adipose tissue and invasive hemodynamics in heart failure with preserved ejection fraction. JACC Heart Fail 2020;8:667–676.

55. Sood A. Altered resting and exercise respiratory physiology in obesity. Clin Chest Med 2009;30:445–454vii.

56. Kasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol 1992;70:921–924.

57. Robertson J, Schaufelberger M, Lindgren M, et al. Higher body mass index in adolescence predicts cardiomyopathy risk in midlife. Circulation 2019;140:117–125.

58. Robertson J, Lindgren M, Schaufelberger M, et al. Body mass index in young women and risk of cardiomyopathy: a long-term follow-up study in Sweden. Circulation 2020;141:520–529.

59. Amdahl MB, Sundaram V, Reddy YNV. Obesity in heart failure with reduced ejection fraction: time to address the elephant in the room. Cardiol Clin 2023;41:537–544.

60. Bozkurt B, Aguilar D, Deswal A, et al.; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Hypertension; and Council on Quality and Outcomes Research. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association. Circulation 2016;134:e535–e578.

61. Vest AR, Chan M, Deswal A, et al. Nutrition, obesity, and cachexia in patients with heart failure: a consensus statement from the Heart Failure Society of America Scientific Statements Committee. J Card Fail 2019;25:380–400.

62. Talha KM, Anker SD, Butler J. SGLT-2 inhibitors in heart failure: a review of current evidence. Int J Heart Fail 2023;5:82–90.

63. James WP, Caterson ID, Coutinho W, et al.; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905–917.

64. Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA’s assessment of two drugs for chronic weight management. N Engl J Med 2012;367:1577–1579.

65. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341–1352.

66. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20:330–342.

67. Beck-da-Silva L, Higginson L, Fraser M, Williams K, Haddad H. Effect of orlistat in obese patients with heart failure: a pilot study. Congest Heart Fail 2005;11:118–123.

68. Muls E, Kolanowski J, Scheen A, Van Gaal L, ObelHyx Study Group. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001;25:1713–1721.

69. Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002;20:1873–1878.

70. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131–2157.

71. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013;17:819–837.

72. Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol 2023;20:463–474.

73. McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocr Rev 2021;42:101–132.

74. Baggio LL, Yusta B, Mulvihill EE, et al. GLP-1 receptor expression within the human heart. Endocrinology 2018;159:1570–1584.

75. Heuvelman VD, Van Raalte DH, Smits MM. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. Cardiovasc Res 2020;116:916–930.

76. Pi-Sunyer X, Astrup A, Fujioka K, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11–22.

77. Marso SP, Daniels GH, Brown-Frandsen K, LEADER Steering Committee, et al; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311–322.

78. Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989–1002.

79. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221–2232.

80. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834–1844.

81. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021;9:653–662.

82. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7:776–785.

83. Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017;19:69–77.

84. Marso SP, Baeres FMM, Bain SC, et al.; LEADER Trial Investigators. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure. J Am Coll Cardiol 2020;75:1128–1141.

85. Margulies KB, Hernandez AF, Redfield MM, et al.; NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016;316:500–508.

86. Deanfield J, Verma S, Scirica BM, et al.; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet 2024;404:773–786.

87. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al.; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069–1084.

88. Kosiborod MN, Petrie MC, Borlaug BA, et al.; STEP-HFpEF DM Trial Committees and Investigators. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 2024;390:1394–1407.

89. Butler J, Shah SJ, Petrie MC, et al.; STEP-HFpEF Trial Committees and Investigators. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet 2024;403:1635–1648.

90. Hollstein T, Schlicht K, Krause L, et al. Effect of various weight loss interventions on serum NT-proBNP concentration in severe obese subjects without clinical manifest heart failure. Sci Rep 2021;11:10096.

91. Kosiborod MN, Deanfield J, Pratley R, et al.; SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM Trial Committees and Investigators. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet 2024;404:949–961.

92. Sundaram V. Glucagon-like peptide-1 receptor agonist in obese heart failure with preserved ejection fraction and type 2 diabetes mellitus. Paper presented at: Late breaking science: registries. In : Proceedings of the Heart Failure 2024; 2024 May 11–14; Lisbon, Portugal. 93. Borlaug BA, Kitzman DW, Davies MJ, et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med 2023;29:2358–2365.

94. Shah SJ, Sharma K, Borlaug BA, et al. Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials. Eur Heart J 2024;45:3254–3269.

95. Schou M, Petrie MC, Borlaug BA, et al.; STEP-HFpEF Trial Committees and Investigators. Semaglutide and NYHA functional class in obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF program. J Am Coll Cardiol 2024;84:247–257.

96. Petrie MC, Borlaug BA, Butler J, et al.; STEP-HFpEF Trial Committees and Investigators. Semaglutide and NT-proBNP in obesity-related HFpEF: insights from the STEP-HFpEF program. J Am Coll Cardiol 2024;84:27–40.

97. Patel R, Wadid M, Makwana B, et al. GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors. JACC Heart Fail 2024;12:1814–1826.

98. Zhang M, Lin C, Cai X, et al. One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA. Diabetes Obes Metab 2025;27:806–815.